Julie Lemieux, MD, on Letrozole in Postmenopausal Early-Stage Breast Cancer: Patient-Reported Outcomes
2016 ASCO Annual Meeting
Julie Lemieux, MD, of Centre Hospitalier Universitaire de Québec, discusses patient-reported outcomes from a study extending adjuvant letrozole for 5 years after completing an initial 5 years of aromatase inhibitor therapy alone or preceded by tamoxifen (Abstract LBA506). To see the French language version of this discussion, click here.
The
Lisa A. Carey, MD, of the University of North Carolina, and Julie Gralow, MD, of the University of Washington, discuss the most important data presented this year on treating breast malignancies (Abstracts LBA1, 500, and 507).
John D. Hainsworth, MD, of the Sarah Cannon Research Institute, discusses early findings from this umbrella basket study on targeted treatment, outside of current drug indications, for different types of advanced solid tumors (Abstract LBA11511).
Richard L. Schilsky, MD, ASCO’s Chief Medical Officer, discusses the key presentations at this year’s conference.
Rakesh Chopra, MD, of the Artemis Health Institute, and Mary Gospodarowicz, MD, of Princess Margaret Hospital, discuss oncology from an international point of view.
Richard L. Schilsky, MD (right), Chief Medical Officer of ASCO, talks with incoming ASCO CEO Clifford A. Hudis, MD (left) and outgoing CEO Allen S. Lichter, MD (center) about the passing of the torch and their perspectives on past accomplishments and future goals of the society.
